Indivior PLC/ GB00BN4HT335 /
5/31/2024 10:00:00 PM | Chg. +0.2500 | Volume | Bid10:03:37 PM | Ask10:03:37 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
18.3200USD | +1.38% | 54,977 Turnover: 792,900.4970 |
17.8100Bid Size: 100 | 18.9600Ask Size: 100 | 2.53 bill.USD | - | 1,841.24 |
GlobeNewswire
5/31
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
GlobeNewswire
4/18
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
4/11
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire
4/3
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire
3/5
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
1/31
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire
11/23/2023
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
Newsfile Corp
10/31/2023
Pharma and Biotech Business Development Leaders to Discuss Psychedelics Partnering at Wonderland